1. A composition comprising: (1) a docosanoid active agent; (2) a first non-ionic surfactant; and (3) a second non-ionic surfactant; and (4) an ophthalmically
acceptable carrier,

wherein the total surfactant concentration is lower than the surfactant concentration which would be required to solubilize the docosanoid active agent for either individual non-ionic surfactant.

2. A composition of claim 1, wherein said non-ionic surfactants are selected from the group consisting of selected from the group consisting of polyoxyethylene sorbitan fatty acid esters, polyoxyethylene alkyl ethers, and mixtures thereof.

3. A composition of claim 2, wherein said first non-ionic surfactant is a polyoxyethylene sorbitan fatty acid ester and said second non-ionic surfactant is a polyoxyethylene alkyl ether.

4. A composition of claim 3, wherein said first non-ionic surfactant is a Polysorbate compound and said second non-ionic surfactant is Brij compound.

5. A composition of claim 4, wherein the total non-ionic surfactant concentration in the composition is about 0.3 to 2.0 weight percent.

6. A method of reducing ocular hypertension, which comprises administering to the ocular fluids or ocular tissue an ophthalmic composition comprising: (1) a docosanoid active agent; (2) a first non-ionic surfactant; and (3) a second non-ionic
surfactant; and (4) an ophthalmically acceptable carrier,

wherein the total surfactant concentration is lower than the surfactant concentration which would be required to solubilize the docosanoid active agent for either individual non-ionic surfactant.

7. A method for increasing the effectiveness of a strong preservative in a solution comprising a docosanoid active agent and a non-ionic surfactant, comprising admixing: (1) a docosanoid active agent; (2) a strong preservative; (3) a non-ionic
surfactant which increases solubility of the docosanoid active agent but decreases the preservative effectiveness of the strong preservative; (4) mannitol in an amount sufficient to increase the effectiveness of the strong preservative; and (5) an
ophthalmically acceptable carrier.

8. The method of claim 7, wherein said docosanoid active agent is isopropyl unoprostone, said strong preservative is benzalkonium chloride, and said non-ionic surfactant is polysorbate 80.

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.